Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Financing Activities (2018 - 2025)

KalVista Pharmaceuticals' Cash from Financing Activities history spans 9 years, with the latest figure at $4.7 million for Q2 2025.

  • For Q2 2025, Cash from Financing Activities fell 96.9% year-over-year to $4.7 million; the TTM value through Apr 2025 reached $158.1 million, up 4.87%, while the annual FY2025 figure was $159.7 million, 5.98% up from the prior year.
  • Cash from Financing Activities for Q2 2025 was $4.7 million at KalVista Pharmaceuticals, up from $295000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $150.1 million in Q2 2024 and bottomed at $128000.0 in Q4 2023.
  • The 3-year median for Cash from Financing Activities is $295000.0 (2024), against an average of $22.7 million.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 1370.59% in 2024 before it crashed 96.9% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $128000.0 in 2023, then skyrocketed by 130.47% to $295000.0 in 2024, then soared by 1479.32% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Cash from Financing Activities are $4.7 million (Q2 2025), $295000.0 (Q4 2024), and $3.0 million (Q3 2024).